[Tanvex-KY] Announcement of Endorsement/Guarantee Pursuant to Article 25, Paragraph 1, Item 4 of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies
Tanvex-KY announced the provision of an endorsement/guarantee of NTD 479.9 million to its 100% subsidiary, Tanvex BioPharma USA, Inc., for financing purposes.
📋 Article Processing Timeline
- 📰 Published: April 22, 2026 at 09:00
- 🔍 Collected: April 23, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: April 23, 2026 at 12:32 (4h 32m after Collected)
1. Date of occurrence: 2026/04/22
2. The company provided with endorsement/guarantee:
(1) Company name: Tanvex BioPharma USA, Inc.
(2) Relationship with the endorsing/guaranteeing company: 100% directly owned subsidiary
(3) Limit of endorsement/guarantee (thousands NTD): 579,634
(4) Original balance of endorsement/guarantee (thousands NTD): 0
(5) Amount of newly added endorsement/guarantee (thousands NTD): 479,925
(6) Balance of endorsement/guarantee up to the date of occurrence (thousands NTD): 479,925
(7) Actual utilized amount by the guaranteed company (thousands NTD): 0
(8) Reason for newly added endorsement/guarantee: Providing financing guarantee for subsidiary Tanvex BioPharma USA, Inc.
3. Collateral provided by the guaranteed company:
(1) Content: None
(2) Value (thousands NTD): 0
4. Latest financial statements of the guaranteed company:
(1) Capital (thousands NTD): 17,310,307
(2) Accumulated profit/loss (thousands NTD): -17,185,204
5. Conditions for lifting endorsement/guarantee liability:
(1) Conditions: As per contract terms
(2) Date: As per contract terms
6. Total limit of endorsement/guarantee (thousands NTD): 1,159,268
7. Balance of endorsement/guarantee up to the date of occurrence (thousands NTD): 479,925
8. Ratio of endorsement/guarantee balance to the net worth of the latest financial statements: 8.28%
9. Ratio of total endorsement/guarantee, long-term investment, and loans to the net worth of the latest financial statements: 8.28%
10. Other matters to be specified: None
2. The company provided with endorsement/guarantee:
(1) Company name: Tanvex BioPharma USA, Inc.
(2) Relationship with the endorsing/guaranteeing company: 100% directly owned subsidiary
(3) Limit of endorsement/guarantee (thousands NTD): 579,634
(4) Original balance of endorsement/guarantee (thousands NTD): 0
(5) Amount of newly added endorsement/guarantee (thousands NTD): 479,925
(6) Balance of endorsement/guarantee up to the date of occurrence (thousands NTD): 479,925
(7) Actual utilized amount by the guaranteed company (thousands NTD): 0
(8) Reason for newly added endorsement/guarantee: Providing financing guarantee for subsidiary Tanvex BioPharma USA, Inc.
3. Collateral provided by the guaranteed company:
(1) Content: None
(2) Value (thousands NTD): 0
4. Latest financial statements of the guaranteed company:
(1) Capital (thousands NTD): 17,310,307
(2) Accumulated profit/loss (thousands NTD): -17,185,204
5. Conditions for lifting endorsement/guarantee liability:
(1) Conditions: As per contract terms
(2) Date: As per contract terms
6. Total limit of endorsement/guarantee (thousands NTD): 1,159,268
7. Balance of endorsement/guarantee up to the date of occurrence (thousands NTD): 479,925
8. Ratio of endorsement/guarantee balance to the net worth of the latest financial statements: 8.28%
9. Ratio of total endorsement/guarantee, long-term investment, and loans to the net worth of the latest financial statements: 8.28%
10. Other matters to be specified: None